All In Biotech

Drug Trial Radar · NCT03836261

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination With Venetoclax With and Without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutation (AMPLIFY)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 984 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

984

Actual

Start

Feb 25, 2019

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Acerta Pharma BVAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Feb 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • AcalabrutinibDrug

    Acalabrutinib,

  • VenetoclaxDrug

    Venetoclax

  • ChemoimmunotherapyDrug

    fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)

  • ObinutuzumabDrug

    Obinutuzumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of acalabrutinib with venetoclax (Arm A) compared to chemoimmunotherapy fludarabine/cyclophosphamide/rituximab [FCR] or bendamustine/rituximab [BR] (Arm C): PFSTime frame: 6 years

Locations

169 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Redondo Beach, California

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Wichita, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    New York, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Canton, Ohio

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Fort Sam Houston, Texas

  • Research Site

    Spokane, Washington

  • Research Site

    Tacoma, Washington

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Capital Federal, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Adelaide, Australia

  • Research Site

    Darlinghurst, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Nedlands, Australia

  • Research Site

    Waratah, Australia

  • Research Site

    Woolloongabba, Australia

  • Research Site

    Krems, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Goiânia, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.